**
In a significant development concerning the ongoing legal battles surrounding glyphosate, the active ingredient in Bayer’s herbicides, internal government records reveal that key officials from the Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, last year. This meeting took place on June 17, just months before the Trump administration initiated actions that appeared to bolster Bayer’s position in its Supreme Court litigation regarding the herbicide, widely associated with cancer claims.
Meeting Details and Context
The meeting involved Anderson and two other senior Bayer executives, signalling a strong connection between the pharmaceutical giant and high-level government officials. The discussions reportedly centred on “litigation” issues, including potential Supreme Court actions aimed at addressing the numerous lawsuits filed against Bayer by individuals claiming that their use of glyphosate products, such as Roundup, resulted in cancer.
These lawsuits hinge on allegations that Bayer neglected to adequately warn consumers about cancer risks linked to glyphosate. The stakes are high, as Bayer has already incurred substantial costs in settlements and jury verdicts, amounting to billions of dollars.
Bayer’s strategy to mitigate its legal exposure involves persuading the Supreme Court to adopt its argument that if the EPA does not mandate a cancer warning on glyphosate products, then Bayer should not be held liable for failing to issue such a warning. The meeting with the EPA, as noted in an internal email, was positioned as an opportunity for Bayer to provide updates on its litigation status and discuss labelling options.
Administration Support Following the Meeting
The Trump administration’s backing of Bayer has been evident since the June meeting. For instance, just days later, on June 29, the Supreme Court solicited input from the Justice Department regarding whether it should hear Bayer’s case. This request coincided with a series of actions taken by the administration to support the company’s interests.
On December 1, 2025, the Trump-appointed Solicitor General, D. John Sauer, submitted a brief advocating for the Supreme Court’s consideration of Bayer’s case, which the Court agreed to hear on April 27, 2026. Furthermore, the White House invoked the Defense Production Act on February 18, 2026, to safeguard the production of glyphosate, effectively providing what some critics describe as “immunity” for manufacturers like Bayer.
Concerns Over Corporate Influence
The implications of this meeting have raised eyebrows among environmental advocates and legal experts. Nathan Donley, the Environmental Health Science Director at the Center for Biological Diversity, expressed concern that the meeting exemplifies a troubling trend where corporations wield significant influence over regulatory decisions that affect public health.
“It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” Donley remarked. The internal communications obtained through a Freedom of Information Act request reveal a concerted effort to engage with Bayer at a level that ordinary citizens affected by glyphosate exposure do not experience.
Legal experts have echoed these sentiments. Whitney Di Bona, a consumer safety advocate, questioned the fairness of a process where a major pesticide manufacturer can engage in private discussions with regulatory bodies while those harmed by its products are left out. Naomi Oreskes, a Harvard professor, noted that the meeting aligns with a broader pattern of corporate leaders gaining access to government officials, further entrenching the disparity between corporate interests and public health.
Responses from Bayer and the EPA
In response to the scrutiny surrounding the meeting, Bayer maintained that such interactions are standard within the regulatory framework. A spokesperson asserted that the company has been transparent regarding its position on glyphosate litigation and that it engages with various stakeholders, including non-governmental organisations.
The EPA, through its press secretary Brigit Hirsh, characterised the meeting as a “standard introductory meeting” and sought to downplay its significance by asserting that it did not specifically pertain to ongoing litigation. However, the planning documents indicating discussions of legal issues raise questions about the agency’s commitment to impartiality.
Why it Matters
The revelations surrounding the meeting between Bayer executives and EPA officials illuminate the complexities of regulatory oversight in the face of corporate power. As the legal battles over glyphosate continue, the intersection of politics, business interests, and public health remains critically important. The outcomes of these discussions could significantly influence regulatory frameworks and public perception of safety concerning widely used herbicides. With implications for both consumer protection and environmental health, stakeholders must scrutinise the relationships between corporations and regulatory bodies to ensure that public health remains the priority in policymaking processes.
